Company:  ONCORUS, INC. (ONCR)
Form Type:  8-K
Filing Date:  6/23/2022 
CIK:  0001671818 
Address:  4 CORPORATE DRIVE 
City, State, Zip:  ANDOVER, Massachusetts 01810 
Telephone:  857-320-6400 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$0.11  
Change: 
0.004 (4.02%)  
Trade Time: 
Jun 07  
Market Cap: 
$2.77M
Trade ONCR now with 

© 2023  
Description of Business
We are a preclinical-stage biopharmaceutical company focused on the intravenous administration of self-amplifying RNA to transform outcomes for cancer patients. We believe that our product candidates have the potential to bring significant benefit to patients who are currently underserved by approved immuno-oncology therapies, including other viral immunotherapies and immune checkpoint inhibitors. Our self-amplifying RNA immunotherapy platform improves upon key characteristics of this therapeutic class to enhance systemic activity. Our approach involves encapsulating genomes of RNA viruses known to kill cancer cells within a lipid nanoparticle, or LNP, creating a selectively self-amplifying vRNA immunotherapy to be administered intravenously, or IV.
Register and access this filing in:     
  FORM 8-K
    SECTION 5 CORPORATE GOVERNANCE
      Item 5.02 Departure of Directors or Certain Officers; ...
      Item 5.07 Submission of Matters to a Vote of Security Holders.
    SECTION 7 REGULATION FD
      Item 7.01 Regulation FD Disclosure.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01 Financial Statements and Exhibits.
    SIGNATURES
  EXHIBIT 99.1


EDGAR® and SEC® are trademarks of the U.S. Securities and Exchange Commission. OTC Markets Group Inc.'s products and services are not affiliated with or approved by the U.S. Securities and Exchange Commission.